AustralianSuper Pty Ltd Buys 170,247 Shares of Insulet Corporation $PODD

AustralianSuper Pty Ltd increased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 487.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 205,168 shares of the medical instruments supplier’s stock after acquiring an additional 170,247 shares during the quarter. AustralianSuper Pty Ltd owned about 0.29% of Insulet worth $64,460,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of PODD. American Century Companies Inc. increased its position in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after acquiring an additional 297,734 shares during the period. Nuveen LLC bought a new position in Insulet during the first quarter worth $74,163,000. Kayne Anderson Rudnick Investment Management LLC increased its position in Insulet by 1,316.5% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock worth $50,818,000 after acquiring an additional 179,850 shares during the period. Vanguard Group Inc. increased its position in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after acquiring an additional 178,976 shares during the period. Finally, Allianz Asset Management GmbH increased its position in Insulet by 89.1% during the second quarter. Allianz Asset Management GmbH now owns 262,878 shares of the medical instruments supplier’s stock worth $82,591,000 after acquiring an additional 123,862 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Barclays boosted their target price on shares of Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Royal Bank Of Canada boosted their price target on shares of Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a report on Friday, October 10th. Wells Fargo & Company boosted their price target on shares of Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, August 8th. JPMorgan Chase & Co. boosted their price target on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Finally, Canaccord Genuity Group boosted their price target on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a report on Monday, September 29th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $352.11.

Insulet Stock Down 0.8%

Shares of NASDAQ:PODD opened at $320.91 on Monday. Insulet Corporation has a 52 week low of $226.50 and a 52 week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The company’s fifty day moving average is $327.60 and its 200-day moving average is $305.11. The company has a market capitalization of $22.59 billion, a PE ratio of 97.54, a P/E/G ratio of 2.68 and a beta of 1.40.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the previous year, the company earned $0.55 EPS. The firm’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Laetitia Cousin sold 797 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.